{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:16:16Z","timestamp":1784139376431,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11060-018-2795-7","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T10:46:43Z","timestamp":1518778003000},"page":"299-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity"],"prefix":"10.1007","volume":"138","author":[{"given":"Rifaquat","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Niemierko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin S.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,16]]},"reference":[{"key":"2795_CR1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1042-3680(18)30365-6","volume":"7","author":"JD Johnson","year":"1996","unstructured":"Johnson JD, Young B (1996) Demographics of brain metastasis. Neurosurg Clin N Am 7:337\u2013344","journal-title":"Neurosurg Clin N Am"},{"key":"2795_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","volume":"88","author":"JH Sampson","year":"1998","unstructured":"Sampson JH, Carter JH, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88:11\u201320. \n                    https:\/\/doi.org\/10.3171\/jns.1998.88.1.0011","journal-title":"J Neurosurg"},{"key":"2795_CR3","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 33:1889\u20131894. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.56.2736","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2795_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459\u2013465. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(12)70090-6","journal-title":"Lancet Oncol"},{"key":"2795_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31601-X","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet Lond Engl. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)31601-X","journal-title":"Lancet Lond Engl"},{"key":"2795_CR6","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17:976\u2013983. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30053-5","journal-title":"Lancet Oncol"},{"key":"2795_CR7","doi-asserted-by":"crossref","unstructured":"Long GV, Atkinson V, Menzies AM et al (2017) A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). J Clin Oncol 35:9508","DOI":"10.1200\/JCO.2017.35.15_suppl.9508"},{"key":"2795_CR8","doi-asserted-by":"crossref","unstructured":"Tawbi HA-H, Forsyth PA, Algazi AP et al (2017) Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204. J Clin Oncol 35:9507","DOI":"10.1200\/JCO.2017.35.15_suppl.9507"},{"key":"2795_CR9","doi-asserted-by":"publisher","first-page":"e498-509","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG (2015) Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16:e498-509. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00007-8","journal-title":"Lancet Oncol"},{"key":"2795_CR10","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1002\/cncr.30138","volume":"122","author":"JM Qian","year":"2016","unstructured":"Qian JM, Yu JB, Kluger HM, Chiang VLS (2016) Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 122:3051\u20133058. \n                    https:\/\/doi.org\/10.1002\/cncr.30138","journal-title":"Cancer"},{"key":"2795_CR11","doi-asserted-by":"publisher","DOI":"10.3171\/2016.9.JNS161585","author":"O Cohen-Inbar","year":"2017","unstructured":"Cohen-Inbar O, Shih H-H, Xu Z et al (2017) The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. J Neurosurg 1\u20138. \n                    https:\/\/doi.org\/10.3171\/2016.9.JNS161585","journal-title":"J Neurosurg"},{"key":"2795_CR12","doi-asserted-by":"publisher","first-page":"e101764","DOI":"10.1371\/journal.pone.0101764","volume":"9","author":"Z Belcaid","year":"2014","unstructured":"Belcaid Z, Phallen JA, Zeng J et al (2014) Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PloS ONE 9:e101764. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0101764","journal-title":"PloS ONE"},{"key":"2795_CR13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","volume":"92","author":"AP Kiess","year":"2015","unstructured":"Kiess AP, Wolchok JD, Barker CA et al (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:368\u2013375. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2795_CR14","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman A, Walavalkar V et al (2017) Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res Off J Am Assoc Cancer Res 23:4242\u20134250. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3133","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2795_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11940-017-0449-2","volume":"19","author":"AS Berghoff","year":"2017","unstructured":"Berghoff AS, Preusser M (2017) Targeted therapies for melanoma brain metastases. Curr Treat Options Neurol 19:13. \n                    https:\/\/doi.org\/10.1007\/s11940-017-0449-2","journal-title":"Curr Treat Options Neurol"},{"key":"2795_CR16","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res Off J Am Assoc Cancer Res 15:7412\u20137420. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1624","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2795_CR17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1741","author":"S Champiat","year":"2016","unstructured":"Champiat S, Dercle L, Ammari S et al (2016) Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1. Clin Cancer Res. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1741","journal-title":"Clin Cancer Res"},{"key":"2795_CR18","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/neuonc\/nov093","volume":"17","author":"KR Patel","year":"2015","unstructured":"Patel KR, Lawson DH, Kudchadkar RR et al (2015) Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro-Oncol 17:1312\u20131321. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nov093","journal-title":"Neuro-Oncol"},{"key":"2795_CR19","doi-asserted-by":"publisher","first-page":"e1046028","DOI":"10.1080\/2162402X.2015.1046028","volume":"4","author":"RA Chandra","year":"2015","unstructured":"Chandra RA, Wilhite TJ, Balboni TA et al (2015) A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 4:e1046028. \n                    https:\/\/doi.org\/10.1080\/2162402X.2015.1046028","journal-title":"Oncoimmunology"},{"key":"2795_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11060-015-1881-3","volume":"125","author":"ZA Kohutek","year":"2015","unstructured":"Kohutek ZA, Yamada Y, Chan TA et al (2015) Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J Neurooncol 125:149\u2013156. \n                    https:\/\/doi.org\/10.1007\/s11060-015-1881-3","journal-title":"J Neurooncol"},{"key":"2795_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3171\/2015.6.JNS142763","volume":"125","author":"RJ Colaco","year":"2016","unstructured":"Colaco RJ, Martin P, Kluger HM et al (2016) Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg 125:17\u201323. \n                    https:\/\/doi.org\/10.3171\/2015.6.JNS142763","journal-title":"J Neurosurg"},{"key":"2795_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s11060-017-2470-4","volume":"133","author":"P Fang","year":"2017","unstructured":"Fang P, Jiang W, Allen P et al (2017) Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. J Neurooncol 133:595\u2013602. \n                    https:\/\/doi.org\/10.1007\/s11060-017-2470-4","journal-title":"J Neurooncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-018-2795-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2795-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2795-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,17]],"date-time":"2019-02-17T02:23:31Z","timestamp":1550370211000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-018-2795-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,16]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["2795"],"URL":"https:\/\/doi.org\/10.1007\/s11060-018-2795-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,16]]},"assertion":[{"value":"12 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Keith T. Flaherty is a consultant for Merck, Bristol-Myers Squibb, and Genentech. Ryan J. Sullivan is a consultant for Merck and Novartis. Kevin S. Oh has received research funding from Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}